Swedish Orphan Biovitrum AB (publ) (SWOBY)
OTCMKTS · Delayed Price · Currency is USD
18.38
-1.23 (-6.27%)
At close: Jan 30, 2026
SWOBY Revenue
In the year 2025, Swedish Orphan Biovitrum AB had annual revenue of 28.24B SEK with 8.50% growth. Swedish Orphan Biovitrum AB had revenue of 7.82B in the quarter ending December 31, 2025, with 5.19% growth.
Revenue
28.24B SEK
Revenue Growth
+8.50%
P/S Ratio
5.18
Revenue / Employee
14.96M SEK
Employees
1,888
Market Cap
15.86B USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 28.24B | 2.21B | 8.50% |
| Dec 31, 2024 | 26.03B | 3.90B | 17.65% |
| Dec 31, 2023 | 22.12B | 3.33B | 17.74% |
| Dec 31, 2022 | 18.79B | 3.26B | 21.00% |
| Dec 31, 2021 | 15.53B | 268.00M | 1.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sofgen Pharma | 423.75M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 196.17M |
| MariMed | 157.38M |
| Elite Pharmaceuticals | 122.89M |
| Earth Science Tech | 33.84M |
| Radnostix | 14.07M |
| Healthy Extracts | 3.59M |